3644 results for «2909»
3644 results
Selection of the 2024 best clinical cases
17 Feb 2024 – From PCR Tokyo Valves 2024
Explore the most outstanding clinical cases from PCR Tokyo Valves 2024, including a nightmare case with bicuspid aortic valve, pharmaco-invasive management of mechanical valve thrombus with cardiogenic shock, and a TAVR-in-TAVR challenge.
Rapid-fire - Tricuspid valve interventions in various situations
17 Feb 2024 – From PCR Tokyo Valves 2024
Explore a diverse range of tricuspid valve interventions through various rapid-fire case studies. Learn about a successful TEER of torrential pentacuspid tricuspid regurgitation, gain insight into a percutaneous transcatheter balloon valvuloplasty as a bridge therapy for bioprosthetic tricuspid stenosis, and more!
Selection of the 2024 best abstracts
17 Feb 2024 – From PCR Tokyo Valves 2024
Explore the most outstanding abstracts from PCR Tokyo Valves 2024, such as a study on the disparity in impact of bleeding after TAVI on long-term mortality between Asian and Nordic population, learning about two-year clinical outcomes of staged transcatheter mitral edge-to-edge repair after TAVR, and a...
Rapid-fire - Valve-in-Valve TAVI
17 Feb 2024 – From PCR Tokyo Valves 2024
Through these slides, gain valuable insights into valve-in-valve TAVI from a rapid-fire series of scenarios that cover structural valve deterioration after SAPIEN 3 implantation, a successful aortic valve-in-valve with balloon valve fracture and coronary protection, and TAV-in-SAV for an extremely small failed surgical valve.
Nightmare in mitral valve interventions: sharing solutions together
18 Feb 2024 – From PCR Tokyo Valves 2024
This selection of cases showcase nightmare scenarios during mitral valve interventions. Find out what difficulties might arise during MitraClip procedure, and learn how to prevent complications through optimal treatments and bailouts.
Managing aortic stenosis in patients with longer life expectancy
18 Feb 2024 – From PCR Tokyo Valves 2024
Consult this session to understand what knowledge is needed for discussions with patients concerning lifetime management of valve disease, gain insight into the importance of predictable and precise commissural and coronary alignment for lifetime management, and learn about the indication of TAV-in-TAV and THV explant.
Tricuspid valve interventions
18 Feb 2024 – From PCR Tokyo Valves 2024
Consult this session if you want to understand T-TEER/TTVR procedure, learn about clinical indication and appropriate patient selection for TEER/TTVR based on TRILUMINATE trial/TRISCEND study, and update your knowledge of current transcatheter technologies for tricuspid regurgitation.
Challenging situations in mitral valve interventions
18 Feb 2024 – From PCR Tokyo Valves 2024
This selection of cases showcases a number of challenging situations in mitral valve interventions and how best to resolve them. Among such complications are a severe afterload mismatch following M-TEER in functional mitral regurgitation, a detached clip in the left atrium, and more.
Nightmares in TAVI: sharing solutions together
18 Feb 2024 – From PCR Tokyo Valves 2024
Consult this session to learn more about bailout techniques for TAVI during uncommon complications, such as late coronary obstruction post-TAVI, a migrated self-expandable valve, or a C-tab induced iatrogenic thoracic aortic dissection after Evolut FX implantation.
Rapid-fire - Bailout in SHD
17 Feb 2024 – From PCR Tokyo Valves 2024
Gain valuable insights into the bailout techniques in structural heart disease intervention in this session of rapid-fire submission cases (in Japanese).
Complex diagnosis
17 Feb 2024 – From PCR Tokyo Valves 2024
Gain valuable insights in how to deal with complex diagnoses in this session of rapid-fire submissions cases [in Japanese].
Mastering techniques from basic to complex - Imaging for aortic stenosis
16 Feb 2024 – From PCR Tokyo Valves 2024
Learn to master different imaging techniques for aortic stenosis through these slides. Gain insight into the concomitance of aortic stenosis and coronary artery disease, and learn about the pitfalls of aortic stenosis diagnosis in this session.
Complications during left main PCI: how to manage and how to avoid
20 May 2026 – From EuroPCR 2026
This session addresses the identification, prevention, and management of complications arising during left main percutaneous coronary intervention (PCI). Through detailed case presentations and analyses, it highlights anatomical and procedural risk factors, strategies to anticipate and recognize complications such as stent deformation and coronary perforation, and effective...
Bleeding and thrombotic risk in LAA closure patients
20 May 2026 – From EuroPCR 2026
This session provides a thorough examination of bleeding and thrombotic risks in patients undergoing left atrial appendage (LAA) closure. It reviews risk factors for device-related thrombosis, compares anticoagulation strategies post-procedure, and presents real-world clinical outcomes, particularly in high bleeding risk populations and special groups such as...
Optimising bifurcation PCI: learning from randomised controlled trials
20 May 2026 – From EuroPCR 2026
This session delves into optimizing bifurcation PCI by examining contemporary European practices and outcomes from multiple randomized controlled trials. Key topics include multivessel TALENT trial results, 30-day outcomes of left main PCI with sirolimus-eluting stents from the NAGOMI COMPLEX study, comparative insights from the CROSS-LCX Registry...
Challenging TAVI access: exploring transfemoral boundaries and mastering alternative access
20 May 2026 – From EuroPCR 2026
This session investigates the boundaries of transfemoral access for TAVI and strategies to safely extend its use. It also provides a comprehensive review of facilitated transfemoral TAVI techniques and explores alternative access options, offering critical insights for managing challenging TAVI cases.
TAVI: head-to-head trials
20 May 2026 – From EuroPCR 2026
This session presents head-to-head comparisons of TAVI devices from recent randomized trials and registries. Highlights include three-year outcomes from the SMART trial, two-year data from the LANDMARK trial on contemporary valves, comparisons of intra- and supra-annular self-expanding valves, evaluations in large annuli, the ALLEGRA trial focusing...
Lost, crushed, fractured: stent complications in real life
20 May 2026 – From EuroPCR 2026
This session addresses real-world challenges of stent complications including loss, crushing, and fracture during PCI. Through case-based discussions, it explores complex scenarios such as stent dislodgement, embolisation, and management strategies when initial plans evolve into complicated realities.
All you need to know about interventional therapies for pulmonary embolism
20 May 2026 – From EuroPCR 2026
Focused on interventional therapies for pulmonary embolism, this session guides on establishing and sustaining Pulmonary Embolism Response Teams (PERT), refining patient selection for intervention, choosing appropriate technologies, and identifying intraprocedural markers indicating successful treatment outcomes.
Antithrombotic therapy after TAVI: optimal agents, regimens, and patient selection
20 May 2026 – From EuroPCR 2026
This session critically evaluates antithrombotic therapy following TAVI, addressing optimal agents and regimens tailored to patients with and without atrial fibrillation. It also reviews clinical presentations and management of valve thrombosis post-TAVI, using guideline-based approaches and real-world cases to individualize patient care.
